Catalyst Pharmaceuticals (CPRX) Statistics

Catalyst Pharmaceuticals Inc (CPRX) is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for rare neurological diseases. With a market capitalization of $800 million, CPRX has positioned itself as a leading player in the industry. When analyzing the valuation metrics of CPRX, several factors come into play. The stock currently trades at a price-to-earnings ratio of 20, indicating that investors are willing to pay 20 times the company's earnings for each share. Additionally, the price-to-sales ratio stands at 7, representing the company's revenue relative to its market capitalization.

In terms of fundamentals, CPRX shows promising signs of growth. The stock's revenue per share is $2, indicating a strong sales performance. Furthermore, the enterprise to EBITDA ratio is 10, suggesting that the company's operational cash flow is healthy. CPRX also boasts a profit margin of 15%, demonstrating its ability to generate profits from its operations. However, it is important to note that the company has a total debt of $100 million, which could impact its financial position.